Skip to content

FARAJ PHARMA

Active Risk: not assessed
Private limited companyfounded 2016active for 10 yearsVorstse Steenweg 214, 1060 Sint-Gillis (bij-Brussel), BelgiumKBO/BCE: BE 0657.789.662
Summary

FARAJ PHARMA is a financial institution. The bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €47,642 and a net result of €31,332. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 39% of 9,754 sector peers (NACE 64, financial year 2025). The company has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow ReportCompare
FARAJ PHARMAActive
Risk analysis ReportCompare

Overview

Official details

Source: KBO
Status
Active since 28-06-2016 Normal situation
Activity
Activities of holding companies NACE 64210and 2 others
Joint committee
313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 2021
Establishment unit
2.255.738.067 1060 Sint-Gillis (bij-Brussel), since 28-06-2016
Financial year end
31 December
Peppol
Reachable since 26-11-2025
Company details

Board and ownership

Board
Board & ownership

Financial position

Financial institution: outside the modelBankruptcy probability: sector outside the model
Annual accounts 2025
Profit
€31,332
▲ 6.8%
Equity
€47,642
▲ 81.1%
Total assets
€128,805
▲ 10.4%
Financials
Signalslowers riskGrowing equityneutralLatest accounts filed on timeShow the evidence

Checked score

Outside the general model
Model not applicable to financial institutions
The Checked score measures liquidity, leverage and margins against the norms for trading and manufacturing companies. A bank, insurer or financial holding has a very different balance sheet. Those ratios and the score mean nothing here. So there is no financial strength either.
Bankruptcy probability within 12 months

The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Two signals.
lowers riskneutral
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025
Equity per financial year
1819202122232425
2018 to 2025 · latest year €47,642
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-03-2026, 123 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
123 days early
2024
30 days early
2023
28 days early
2022
45 days early
2021
53 days early
2020
59 days early
2019
43 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 54 days before the deadline. In the sector (NACE 64), the median for financial year 2024 was 14 days before the deadline, and 28% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 16 June (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
03-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Key points

  • Positive: 8 profitable years in a rowprofit 2025: €31,332 8 years View
  • Positive: Filed on time since financial year 2019accounts within the deadline every year 7 years View

Recent changes

  1. · Gazette deed Change of role: EL BAYAD Abdellah, from manager to director
  2. · Gazette deed Incorporation
All 13 events

Comparable companies

These companies have the same main activity as FARAJ PHARMA: activities of holding companies (NACE 64210). They are comparable in size and age: total assets between €113,000 and €160,000, founded between 2015 and 2017.

CompanyTotal assetsGross margin
FARAJ PHARMA Sint-Gillis (bij-Brussel)€128,805€44,273
SOFFIA-MP Sint-Gillis (bij-Brussel)€159,809€43,248
BERT BAEKELANDT Middelkerke€122,007€44,447
Zorro Brasschaat€125,188€40,573
PHJ CONSTRUCT Knokke-Heist€123,485€42,655
BIG STEPS CONSULTING Asse€113,443€46,795
CLAMONTA Deinze€146,551€41,644
Full comparison

Key facts about FARAJ PHARMA
What is the company number of FARAJ PHARMA?
The company number of FARAJ PHARMA is 0657.789.662. The VAT number is the same number with BE in front: BE 0657.789.662.
Where is FARAJ PHARMA based?
The registered office is at Vorstse Steenweg 214, 1060 Sint-Gillis (bij-Brussel).Company details
What does FARAJ PHARMA do?
According to the KBO register, the main activity is activities of holding companies (NACE 64210).
What is the legal form of FARAJ PHARMA?
The legal form of FARAJ PHARMA is Private limited company (BV).
When was FARAJ PHARMA founded?
FARAJ PHARMA was founded on 28-06-2016.
Is FARAJ PHARMA still active?
Yes, FARAJ PHARMA is an active enterprise in the KBO register.
How many employees does FARAJ PHARMA have?
FARAJ PHARMA had an average of 0.4 full-time equivalents in financial year 2018, according to the filed annual accounts.Financials
Which joint committee does FARAJ PHARMA fall under?
In its 2021 annual accounts, FARAJ PHARMA states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
What is the turnover of FARAJ PHARMA?
The turnover in financial year 2025 is ≈ €180,000. This figure is estimated from the gross margin of €44,273 and 2,953 comparable companies of the same size. It probably lies between €110,000 and €320,000. It is a rough estimate.
Is FARAJ PHARMA profitable?
In financial year 2025, FARAJ PHARMA made a profit of €31,332.
Where can I find the annual accounts of FARAJ PHARMA?
FARAJ PHARMA filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of FARAJ PHARMA due?
FARAJ PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See what changed in the latest annual accounts.What changed See this company's board, registered office and name on a given date.Company as of a date

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure